Few studies have reported reduced MTA3 expression in certain highly metastatic CRC cell lines, with lower levels correlating with worse clinical outcomes (55), indicating a context-dependent dual role for MTA3 in CRC metastasis. The gene discussed is MTA3; the disease is colorectal carcinoma.